natgillin/translations-raw huggingface dataset:
for a compound of Formula I where X is O, coupling a corresponding compound having the formula VIII with a corresponding compound having the formula III in the presence of a base; or 
za spoj s formulom I gdje X je O, sparivanje odgovarajućeg spoja koji ima formulu VIII [image] s odgovarajućim spojem koji ima formulu III [image] u prisutnosti baze; ili
A compound for use as defined in claim 18, wherein the pain is chronic pain. 
Spoj za uporabu kako je definiran u zahtjevu 18, naznačen time da bol je kronična bol.
A compound for use as defined in claim 18, wherein the pain is acute pain. 
Spoj za uporabu kako je definiran u zahtjevu 18, naznačen time da bol je akutna bol.
A compound for use as defined in claim 22, wherein said cancer is a cancer having a dysregulation of TrkA. 
Spoj za uporabu kako je definiran u zahtjevu 22, naznačen time da navedeni rak je rak koji ima poremećaj regulacije TrkA.
Amisulpride for use according to claim 1 or 2, to be administered by rectal, intranasal, buccal, oral, transdermal, sublingual or inhaled administration. 
Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se primjenjuje rektalnom, intranazalnom, bukalnom, oralnom, transdermalnom, sublingvalnom ili inhalacijskom primjenom.
The locking device (1) according to claim 1, wherein the movement system has at least one gear unit (5), and wherein the at least one gear unit (5) is driven by rotary movement of the at least one electric motor (4) and causes rotation of the at least one shaft. 
Zaporni uređaj (1) prema bilo kojem od prethodnih zahtjeva, naznačen time, da pokretački sustav ima najmanje jednu jedinicu zupčanika (5), posebno najmanje jedan uglasti zupčanik, pri čemu se navedena najmanje jedna jedinica zupčanika (5) pogoni pomoću rotacijskog pokretanja najmanje jednog električnog motora (4) i uzrokuje rotaciju osovine pokretačkog sustava.
A method for treating a viscous fatty mass that comprises solid components in a grinding system, said grinding system comprising a mixer and a grinding device, the method comprising the steps of: 
Postupak obrade viskozne mase koja sadrži čvrste komponente u sustavu za mljevenje, osobito masne mase s čvrstim komponentama, gdje navedeni sustav za mljevenje sadrži miješalicu i napravu za mljevenje, gdje se navedeni postupak sastoji u koracima:
feeding into the mixer the mass to be treated, repeatedly circulating the mass to be treated by means of a displacement device from the mixer through a supply pipe to the grinding device and through a return pipe back to the mixer for reducing the size of said solid components in said grinding device, 
– dodavanja u miješalicu mase koju treba obraditi, – ponovljenog cirkuliranja mase koju treba obraditi uz pomoć naprave za pomicanje iz miješalice kroz dovodnu cijev u napravu za mljevenje i kroz povratnu cijev natrag u miješalicu radi smanjivanja veličine navedenih čvrstih komponenata u navedenoj napravi za mljevenje, gdje je navedena naprava za mljevenje kuglični mlin, naznačen time što postupak također uključuje korak:
The method according to claim 1, wherein said fatty mass is a mass comprising at least one of the following components: cocoa mass, milk powder, whey powder, lecithin, flavor, and sugar. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedena masna masa masa koja sadrži najmanje jednu od sljedećih komponenata: kakaovu masu, mlijeko u prahu, sirutku u prahu, lecitin, aromu i šećer.
The method according to claim 1, wherein a volume of the new mass to be treated is larger than the mixer's volume. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je volumen nove mase koju treba obraditi veći od volumena miješalice.
The method according to claim 1, wherein the system comprises a storage vessel the volume of which is larger than the mixer's volume. A grinding system for performing a method according to claim 1, wherein the grinding system comprises the mixer and the grinding device, said mixer being connected to the grinding device by means of the supply pipe and the displacement device being provided for displacing said mass from said mixer to the grinding device, and said grinding device being connected to said mixer by means of the return pipe, wherein the branch off is provided in said return pipe for removing treated mass from said system. 
Sustav za mljevenje, namijenjen provedbi postupka u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje sustav za mljevenje sadrži miješalicu i napravu za mljevenje, gdje je navedena naprava za mljevenje kuglični mlin, gdje je navedena miješalica u jednu ruku povezana s napravom za mljevenje putem dovodne cijevi, te je ugrađena naprava za pomicanje navedene mase iz navedene miješalice u napravu za mljevenje, a u drugu ruku je navedena naprava za mljevenje povezana s navedenom miješalicom putem povratne cijevi, naznačen time što se ogranak nalazi u navedenoj povratnoj cijevi za uklanjanje obrađene mase iz navedenog sustava, te što naprava sadrži spremišnu posudu, gdje je volumen navedene spremišne posude veći od volumena miješalice.
of T lymphocytes which are specific to the tumor-associated antigen or to a part thereof in a biological sample isolated from a patient, with said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
The composition of claim 37 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1Helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
The bispecific antibody or antibody fragment thereof according to one of the claims 1 to 6 comprising a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
The antibody or antibody fragment thereof according to one of the claims 1 to 4 comprising a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
The use according to claim 10 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
A geocell formed from polymeric strips, at least one polymeric strip having a storage modulus of 500 MPa or greater when measured in the machine direction by Dynamic Mechanical Analysis (DMA) according to ASTM D4065 at 23°C and at a frequency of 1 Hz. 
Geoćelija (10) načinjena od polimernih traka (14), naznačena time da barem jedna modificirana polimerna traka (14) ima modul pohrane od 500 MPa ili veći kada se mjeri u smjeru obrade pomoću dinamičke mehaničke analize (DMA) prema ASTM D4065 na 23°C i na frekvenciji od 1 Hz.
A geocell formed from polymeric strips, at least one polymeric strip having a storage modulus of 150 MPa or greater when measured in the machine direction by Dynamic Mechanical Analysis (DMA) according to ASTM D4065 at 63°C and at a frequency of 1 Hz. 
Geoćelija (10) prema zahtjevu 1, te barem jedna polimerna traka (14) ima modul pohrane od 150 MPa ili veći kada se mjeri u smjeru obrade pomoću dinamičke mehaničke analize (DMA) prema ASTM D4065 na 63°C i na frekvenciji od 1 Hz.
The geocell of claim 11, wherein the at least one polymeric strip has a stress at 12% strain of 14.5 MPa or greater when measured according to the Izhar procedure at 23°C. 
Geoćelija (10) prema zahtjevu 1, 2 ili 3, naznačena time da barem jedna polimerna traka (14) ima kod 12% istezanja naprezanje od 14.5 MPa ili veće kada se mjeri prema Izharovom postupku na 23°C.
The geocell of claim 11, wherein the at least one polymeric strip has a coefficient of thermal expansion of 120 x 10-6 /°C or less at 25°C according to ASTM D696. 
Geoćelija (10) prema zahtjevu 1, 2 ili 3, naznačena time da barem jedna polimerna traka ima koeficijent toplinskog rastezanja od 120 x 10-6 /°C ili manje na 25°C prema ASTM D696.
The pavement, road, railway, or parking area of claim 7, wherein the geocell is filled with a granular material selected from the group consisting of sand, gravel, crushed stone, ballast, quarry waste, crushed concrete, recycled asphalt, crushed bricks, building debris and rubble, crushed glass, power plant ash, fly ash, coal ash, iron blast furnace slag, cement manufacturing slag, steel slag, and mixtures thereof. 
Pločnik, prometnica, željeznička ili parkirna površina prema zahtjevu 7, naznačena time da je geoćelija ispunjena s granuliranim materijalom odabranim iz skupine koja se sastoji od pijeska, šljunka, drobljenog kamena, balasta, kamenog otpada, drobljenog betona, recikliranog asfalta, drobljene cigle, građevinskih ostataka i šute, drobljenog stakla, pepela iz elektrane, letećeg pepela, ugljenog pepela, troske iz visoke peći, troske iz proizvodnje cementa, troske iz proizvodnje čelika i njihovih mješavina.
The bispecific antibody or antibody fragment for use according to claim 14, wherein the disease is selected from the group consisting of an allergic disease, asthma, cancer, an autoimmune disease, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/-0.20°θ) at about 7.5, 11.75, 13.20 and 19.65; and optionally 
polimorf pokazuje uzorak difrakcije rendgenskih zraka na prašku s karakterističnim vrhovima izraženima u stupnjevima 2θ (+/-0.20° θ) na oko 7,5, 11,75, 13,20 i 19,65; i po izboru
the polymorph exhibits an infrared (IR) spectrum having characteristic peaks at about 1389, 1335 and 1245 cm-1. 
polimorf pokazuje infracrveni (IR) spektar s karakterističnim vrhovima na oko 1389, 1335 i 1245 cm-1.
The crystalline polymorph according to claim 1, wherein the polymorph exhibits a predominant endotherm at a range of about 101-105° C as measured by a Differential Scanning Calorimeter (DSC) at a scan rate of 10° C per minute. 
Kristalni polimorf u skladu s patentnim zahtjevom 1, naznačen time, da polimorf pokazuje predominantnu endotermu u rasponu od oko 101 - 105° C izmjereno diferencijalnim skenirajućim kalorimetrom (DSC) pri brzini skeniranja od 10° C po minuti.
The crystalline polymorph according to claim 1, wherein the polymorph exhibits at least one of the following characteristics: 
Kristalni polimorf u skladu s patentnim zahtjevom 1, naznačen time, da polimorf pokazuje najmanje jednu od sljedećih karakteristika:
an X-ray powder diffraction pattern substantially as shown in Figure 5; 
uzorak difrakcije rendgenskih zraka na prašku, kao što je prikazano na slici 5;
an infrared (IR) spectrum substantially as shown in Figure 6; 
infracrveni (IR) spektar uglavnom kao što je prikazano na slici 6;
a Raman spectrum substantially as shown in Figure 8. 
Raman spektar uglavnom kao što je prikazano na slici 8.
A mixture of the polymorphic Form A and Form B of methyl (E)-2-{2-[6-(2- cyanophenoxy) pyrimidin-4-yloxy] phenyl}-3-methoxyacrylate, wherein Form A is characterized by the following properties: 
Smjesa polimorfnog oblika A i oblika B metil (E)-2-{2-[6-(2-cijanofenoksi)pirimidin -4-iloksi] fenil}- 3-metoksiakrilata, naznačena time, da je oblik A karakteriziran sljedećim svojstvima:
The mixture according to claim 6, wherein the polymorph Form A exhibits a Raman spectrum having characteristic peaks at about 4398, 133029 and 22332 cm-1 
Smjesa u skladu s patentnim zahtjevom 6, naznačena time, da polimorfni oblik A pokazuje Raman spektar s karakterističnim vrhovima na oko 4398, 133029 i 22332 cm-1.
The mixture according to claim 6, wherein the polymorph Form A exhibits a single predominant endotherm at a range of about 114- 117° C as measured by a Differential Scanning Calorimeter (DSC) at a scan rate of 10° C per minute. 
Smjesa u skladu s patentnim zahtjevom 6, naznačena time, da polimorfni oblik A pokazuje jedinu dominantnu endotermu u rasponu od oko 114 - 117° C izmjereno diferencijalnim skenirajućim kalorimetrom (DSC) pri brzini skeniranja od 10° C u minuti.
The mixture according to claim 6, wherein polymorph Form A further exhibits X-ray powder diffraction characteristic peaks expressed in degrees 2θ (+/-0.20°θ) at about 11 and 14.4. 
Smjesa u skladu s patentnim zahtjevom 6, naznačena time, da polimorfni oblik A nadalje pokazuje karakteristične vrhove rendgenske difrakcije na prahu izražene u stupnjevima 2θ (+/-0.20° θ) na oko 11 i 14,4.
The mixture according to claim 6, which exhibits a Differential Scanning Calorimeter (DSC) thermogram substantially as shown in Figure 9. 
Smjesa u skladu s patentnim zahtjevom 6, naznačena time, da je termogram diferencijalnog skenirajućeg kalorimetra (DSC) kao što je prikazano na slici 9.
The process according to claim 11, wherein the organic solvent is selected from the group consisting of 1-propanol and N,N- dimethyl acetamide. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se organsko otapalo bira iz skupine koju čine 1-propanol i N,N-dimetilacetamid.
preparing a solution of methyl (E)-2-{2-[6-(2-cyanophenoxy) pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate in a solvent selected from the group consisting of an alcohol and an amide; 
pripremanje otopine metil (E)-2-{2-[6-(2-cijanofenoksi)pirimidin-4-iloksi]fenil}-3-metoksiakrilata u otapalu odabranom iz skupine koja sadržava alkohol i amid;
adding water to said solution so as to form crystals of said compound; and isolating the crystals. 
dodavanje vode navedenoj otopini tako da se dobiju kristali spomenutog spoja; i
The process according to claim 14 wherein the alcohol is selected from the group consisting of isopropyl alcohol, 1-propanol and butanol. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time, da je alkohol odabran iz skupine koju čine izopropil alkohol, 1-propanol i butanol.
adding an anti-solvent selected from aliphatic and aromatic hydrocarbon to said solution so as to form crystals of said compound; and isolating the crystals. 
dodavanje anti-otapala odabranog između alifatskog i aromatskog ugljikovodika u navedenu otopinu tako da se dobiju kristali spomenutog spoja; i
The occlusion device, according to claim 1, characterised in that each of the clamping jaws (2) has the form of a tube. 
Uređaj za zatvaranje, sukladno patentnom zahtjevu 1, naznačen time što svaka stezaljka (2) ima oblik cijevčice.
The occlusion device, according to claim 1 or 2, characterised in that the internal channels (5) of the clamping jaws (2) have straight symmetry axes. 
Uređaj za zatvaranje, sukladno patentnom zahtjevu 1 ili 2, naznačen time što unutarnji kanali (5) stezaljki (2) imaju ravne simetrije osi.
▪ at least one and at most two Y1, Y2, Y3, and Y4 groups represent a nitrogen atom, and ▪ Y2 and Y4 cannot represent a nitrogen atom at the same time, 
▪ najmanje jedan a najviše dvije od skupina Y1, Y2, Y3 i Y4 predstavljaju dušikov atom, te ▪ Y2 i Y4 ne mogu istodobno predstavljati dušikov atom,
The compound according to claim 3, characterized in that X represents a divalent group selected from S, S(O)2, CH2, SCH2, S(O)2CH2, S(O)2NH, CH2CH2, and C≡C, wherein the first atom of these groups is bound to atom C of chain C -X-Ar. 
Spoj prema patentnom zahtjevu 3, naznačeno time da X predstavlja dvovalentnu skupinu odabranu od S, S(O)2, CH2, SCH2, S(O)2CH2, S(O)2NH, CH2CH2, i C≡C, pri čemu je prvi atom tih skupina vezan na atom C lanca C-X-Ar.
The compound according to claim 5, characterized in that Ar represents a group selected from the following groups: 
Spoj prema patentnom zahtjevu 5, naznačeno time da Ar predstavlja skupinu odabranu od sljedećih skupina: [image] [image]
at least one other active ingredient, such as an anticancer agent, as a combination product for simultaneous, separate or sequential use. 
najmanje jedan drugi aktivni sastojak, kao što je antikancerogeno sredstvo, kao kombinirani proizvod za istodobnu, odvojenu ili sekvencijalnu upotrebu.
each R4 is independently halo, OH, -NH2, -NHR1, -N(R1R1), -COOH, -COOR1, -NHCO-R1; each R5 is independently C1-4 alkyl or H, or two R5 taken together with the nitrogen atom to which they are bound form a 4, 5, or 6 membered saturated heterocyclic ring containing 0 or 1 additional heteroatoms where such additional heteroatom is O or N wherein such heterocycle is optionally substituted with -OH, -NH2, -N(R1R1), n-hydroxy C1-4 alkyl, -(CH2)m-COOH,-(CH2)m-COOR1; and each m is independently 0, 1, 2, or 3. 
svaki R5 je neovisno C1-4 alkil ili H, ili dva R5, uzeta zajedno s atom dušika na kojeg su vezani, tvore 4, 5 ili 6-eročlani zasićeni heterociklički prsten, koji sadrži 0 ili 1 dodatni heteroatom, gdje je takav dodatni heteroatom O ili N, gdje takav heterocikl može biti supstituiran s -OH, -NH2, -N(R1R1), n-hidroksi C1-4 alkilom, -(CH2)m-COOH, -(CH2)m-COOR1; i svaki m je neovisno 0, 1, 2 ili 3.
A method for the synthesis of a compound of Formula I-R or I-S of claims 1-4 comprising a tetrahydronaphthalene moiety having a chiral carbon in the six-membered saturated ring of the tetrahydronaphthalene moiety where the compound is enantiomerically enriched with respect to the chiral carbon, the method comprising the steps of 
Postupak sinteze spoja Formule I-R ili I-S u skladu s patentnim zahtjevima 1-4, koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, gdje je spoj enantiomerno obogaćen u odnosu na kiralni ugljik, naznačen time što se postupak sastoji u koracima
reacting such compound with a chiral reagent to form a chiral center at the tetrahydronaphthalene moiety carbon previously bound to the oxo group. 
reakcije takvog spoja s kiralnim reagensom kako bi se dobilo kiralni centar na ugljiku u tetrahidronaftalenskom ostatku, prethodno vezan na skupinu okso.
The method of claim 8 wherein the method further comprises the step of reversing the chiral configuration of the chiral carbon in the six-membered saturated ring of the tetrahydronaphthalene moiety that was previously bound to the oxo group by treating Formula VI-R or VI-S with diphenylphosphoryl azide (DPPA) to form an azido tetrahydronaphthalene of Formula VII-S or VII-R: where the azido substituent in the six-membered saturated ring of the tetrahydronaphthalene moiety replacing the hydroxy substituent and the chiral carbon that is bound to the azido substituent has a reverse chiral configuration of the chiral carbon when it was previously bound to the hydroxy substituent. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što postupak dodatno uključuje korak reverzije kiralne konfiguracije na kiralnom ugljiku u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka prethodno vezanom na skupinu okso obradom Formule VI-R ili VI-S difenilfosforil-azidom (DPPA) kako bi se dobilo azidotetrahidronaftalen Formule VII-S ili VII-R: [image] [image], gdje supstituent azido u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka zamjenjuje supstituent hidroksi, a kiralni ugljik vezan na supstituent azido ima obratnu kiralnu konfiguraciju na kiralnom ugljiku u odnosu na kada je bio prethodno vezan na hidroksi supstituent.
The method of claim 9 wherein Z is -CN and the method further comprises the step of forming a substituted 1,2,4-oxadiazole on the tetrahydronaphthalene moiety by (a) reacting the intermediate of VII-R or VII-S with a protecting agent and then reacting the resulting protected form of the intermediate of VII-R or VII-S with a hydroxylamine or a hydroxylamine hydrochloride to form a hydroxyamidine at the phenyl carbon to which Z had been attached, the resulting compound of such reaction having the Formula VIII-R or VIII-S: and 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je Z -CN, a postupak dodatno uključuje korak dobivanja supstituiranog 1,2,4-oksadiazola na tetrahidronaftalenskom ostatku reakcijom međuprodukta VII-R ili VII-S sa zaštitnim sredstvom, te reakcijom dobivenog zaštićenog oblika međuprodukta VII-R ili VII-S s hidroksilaminom ili hidroksilamin-hidrokloridom kako bi se dobilo hidroksiamidin na fenilnom ugljiku na kojeg je Z vezan, gdje spoj dobiven takvom reakcijom ima Formulu VIII-R ili VIII-S:
The method of claims 7-11 wherein the resulting compound comprising a tetrahydronaphthalene moiety having a chiral carbon in the six-membered saturated ring of the tetrahydronaphthalene moiety is enantiomerically enriched at least 90%. 
Postupak u skladu s patentnim zahtjevima 7-11, naznačen time što je dobiveni spoj koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, enantiomerno obogaćen najmjanje 90%.
A method for the synthesis of a compound of Formula I-R or I-S of claim 1 comprising a tetrahydronaphthalene moiety having a chiral carbon in the six-membered saturated ring of the tetrahydronaphthalene moiety where the compound is enantiomerically enriched with respect to the chiral carbon, the method comprising the steps of 
Postupak sinteze spoja Formule I-R ili I-S u skladu s patentnim zahtjevom 1, koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, gdje je spoj enantiomerno obogaćen u odnosu na kiralni ugljik, naznačen time što se postupak sastoji u koracima
The formulation according to claim 3, in the form of capsules or tablets. 
Formulacija u skladu sa patentnim zahtjevom 3, u obliku kapsula ili tableta.
The formulation according to claim 3, in the form of tablets. 
Formulacija u skladu sa patentnim zahtjevom 3, u obliku tableta.
The formulation according to claim 8 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau. 
Formulacija u skladu sa patentnim zahtjevom 8 gdje je interferon odabran od interferona alfa 2B, pegiliranog interferona alfa, konsenzusnog interferona, interferona alfa 2A, i limfoblastičnog interferona tau.